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Abstract 
Tumor initiating cells (TICs) differ from normal stem cells (SCs) in their ability to 
initiate tumorigenesis, invasive growth, metastasis and the acquisition of chemo and/or 
radio-resistance.  In the last years, several studies have indicated the potential role of the 
Notch system as a key regulator of cellular stemness and tumor development.  
Furthermore, the expression of cancer testis antigens (CTA) in TICs, and their role in SC 
differentiation and biology, has become an important area of investigation.  Here we 
propose a model in which CTA expression and Notch signaling interacts to maintain the 
sustainability of self-replicating tumor populations, ultimately leading to the development of 
metastasis, drug resistance, and cancer progression.  We hypothesize that Notch-CTA 
interactions in TICs offer a novel opportunity for meaningful therapeutic interventions in 
cancer.   
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Tumor initiating cells: the dark side of stemness  
Stem cells (SCs) are toti-potential cells capable of an unlimited number of 
replication cycles and, under appropriate stimuli, differentiation into more specialized cells.  
This basal cell compartment constitutes the internal repair and self-renewal system in 
normal tissues.  It is this balance between cellular self-renewal and differentiation what 
maintains normal tissue architecture and function.  Therefore, it is not surprising that 
molecular derangements that affect this highly regulated process can lead to uncontrolled 
cellular growth, aberrant differentiation and tumor development.   
The proposed existence of a population of tumor initiating cells (TIC) that mediate 
tumorigenesis and cancer progression has forced us to revisit our understanding of the 
fundamental processes governing cancer development.  Unlike normal SCs, TICs have 
lost their stringent regulation and display a tendency for tumorigenesis, cellular 
invasiveness and metastatic potential [1].  The renewed interest in the study of TIC biology 
stems from the fact that their identification and therapeutic targeting may result, not only 
on improved tumor responses, but also in the potential eradication of neoplastic cells 
associated with pharmacologic resistance and disease relapse.   
Several hypotheses have been proposed to account for the origin and development 
of TICs. The stochastic model suggests that normally differentiated cells can acquire a 
transformed phenotype capable of driving tumorigenesis through clonal evolution. 
Alternatively, the hierarchic model proposes that normal SCs may undergo an oncogenic 
event and subsequently serve as a continuous source of neoplastic cells, intrinsically 
resistant to standard therapeutic interventions. These two views are not necessarily 
mutually exclusive and a combined model may account for tumor development and 
progression, more accurately [2]. For example, TICs may originate either from normal SCs 
or more differentiated progenitors that acquire the capacity for self-renewal, invasive 
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behavior and metastatic potential.  Brabletz et al. has proposed the concept of “migrating 
TICs” (mTICs) which possess both stemness and migratory capabilities associated with 
the acquisition of epithelial-mesenchymal transition (EMT) phenotype [3].  This switch from 
SCs to mTICs appears to relate, not only to genetic alterations, but also to micro-
environmental factors.  These permissive micro-environmental niches may promote TIC 
proliferation and differentiation into invasive and metastatic cell populations, resulting in 
tumor progression and the emergence of resistance to standard treatments.    
TICs are usually characterized by the expression and/or deregulation of genes 
involved in embryonic development, such as the Hedgehog, Notch and Wnt signaling 
pathways.  These three signaling pathways appear to be fundamental in TIC biology and 
represent promising targets for therapeutic intervention [4].  In the next sections we will 
discuss the role of the Notch signaling pathway in cellular stemness and tumorigenesis, as 
well as its interaction with the family of proteins known as cancer testis antigens (CTAs), 
recently found to be expressed on TICs [5]. 
 
The Notch pathway 
The Notch family of proteins includ s a total of four highly homologous receptors 
(Notch-1, Notch-2, Notch-3, Notch-4) with important roles in the regulation of various 
processes, including neurogenesis, gliogenesis, myogenesis, vasculogenesis, 
hematopoiesis and epidermal development [6].  The Notch system is involved in the 
homeostasis of adult tissues by promoting self-renewal of SCs, determining cell fate (such 
as commitment towards T or B cell lineage) and regulating the differentiation of many cell 
types. Because of its extensive involvement in all these processes, mutations and/or 
deregulation of Notch receptors and/or ligands has been associated with the genesis of 
various malignancies [7].  Notch signaling depends on its interaction with specific ligands, 
proteolytic cleavage, release of Notch’s cytoplasmic portion and subsequent translocation 
to the nucleus [8].  In vertebrates, two closely related families of ligands are capable of 
interacting with Notch receptors: the Delta-like (DLL-1, -3, -4 and DLL-2, described only in 
Xenopus) and the Serrate-like (Jagged1 and 2) ligands [9].  Notch signaling is dependent 
on cell-to-cell communication and is activated when Notch ligands, present on the 
“sending cell”, bind to Notch receptor on the “receiving cell”.  Ligand binding triggers 
conformational changes in Notch receptors that allow access to the ADAM/TACE (A 
disintegrin and metalloprotease/tumor-necrosis-factor α converting enzyme) 
metalloprotease. The resulting proteolytic cleavage occurs within the extracellular domain 
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(approximately 12 amino acids proximal to the transmembrane domain), at a site referred 
to as the S2 cleavage site [8].  ADAM/TACE leaves a short-lived fragment anchored to the 
plasma membrane, known as Notch extracellular truncation (NEXT), which is then 
recognized by the inactive aminopeptidase domain of Nicastrin (NCT) and transferred to 
the active site of the enzyme γ-secretase.  γ-secretase operates within the transmembrane 
domain (between site S3, near the inner plasma membrane, and site S4, near the middle 
of the transmembrane domain) and releases the Notch intracellular domain (NICD) whiche 
then translocates to the nucleus (or endoplasmic reticulum), and interacts with the DNA-
binding protein complex CBF-1/RBP-Jk (Cp-binding factor-1/(Recombination signal 
sequence-binding p otein Jk) to regulate transcription of Notch-dependent genes [9, 10].  
NICD transcriptional targets include Hairy/Enhancer of Split (HES) genes, HES-related 
repressor protein (HERP), class C bHLH (basic-helix-loop-helix) proteins acting as 
transcriptional repressors of tissue-specific genes (such as MASH-1 in neurogenesis, 
MyoD  in myogenesis and E2A in B lymphopoiesis), the pre-TCR alpha  (which 
participates in regulating the T cell progenitors differentiation), cell cycle regulatory genes 
such as cyclin D2, cyclin D1, p21 and p27, and genes from different chemokine systems 
[11, 12, 13].   
Notch signaling is involved in the regulation of SC fate, in both embryonic and adult 
tissues.  Activation of the Notch pathway has been shown to regulate the transit of nervous 
SCs from quiescence to a proliferative state and, together with Wnt signaling, also 
coordinates proliferation and differentiation of intestinal SCs [14].  Since deregulation of 
the Notch system has been shown to be involved in the patho-biology of many neoplasms, 
it is not surprising this signaling pathway is of fundamental importance in  the molecular 
processes involved in TIC development.  
 
Notch and TICs 
Activation of the Notch system promotes self-renewal of TICs in several 
malignancies and participates in the interactions between tumor cells and the 
microenvironment, in both primary and metastatic neoplasms [15].  The Notch signaling  
pathway regulates not only the formation of TICs, but also their acquisition of the EMT 
phenotype which promotes metastasis and drug resistance [16].  Notch signaling has been 
demonstrated to be crucial in neural SCs biology based on its ability to inhibit neuronal 
differentiation [17].  The observation that Notch activation up-regulates AKT and MCL-1 
expression in glioma SCs after radiation, indicates its importance in mediating resistance 
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to DNA damage-induced apoptosis [18].  Glioblastoma multiforme (GBM) SCs appear to 
be sensitive to Notch-inhibitors, reflecting the importance of Notch and HES gene family 
activation in their biology.  A study by Shiras et al. demonstrated that Notch blockade can 
reduce the CD133-positive SC fraction and abolished the non SC population in a human 
model of GBM, suggesting this pathway is involved in maintenance of the TIC 
compartment and tumorigenesis [19].  Notch and Wnt pathways also play crucial roles in 
coordinating proliferation and differentiation of intestinal stem cells in mice [14], and their 
activation leads to amplification of the intestinal SC/progenitor cell pool and inhibition of 
cell differentiation [20].  The importance of Notch signaling in gastrointestinal tissues is 
further supported buy its association with chemotherapy resistance in gastric tumors [21] 
and up-regulation of Notch1 and HES1 in colon adenocarcinomas, compared to normally 
differentiated colonic cells [22]. Since maintenance of undifferentiated, proliferative cells in 
intestinal crypts and adenomas requires activation of the Notch pathway, inhibition of 
Notch signaling by γ-secretase inhibitors has been proposed as a treatment for colorectal 
cancer [23].   
The Notch pathway is also deregulated in breast cancer (BC) and its activation may 
protect BCs from drug-induced apoptosis [24, 25].  Indeed, Notch signaling has been 
suggested as one of the conserved developmental pathways leading to TIC maintenance 
and resistance to conventional chemotherapy in this disease [26].  In ovarian cancer (OC) 
Notch3 activation has been associated with chemo-resistance and poor prognosis [27,28].  
McAuliffe et al. have demonstrated over-expression of Notch3 in OC is associated with an 
increased TIC population and development of resistance to cisplatin, while Notch3 
inhibition results in reduction of TICs and restoration of sensitivity to platinum agents [29].  
Aberrations in Notch signaling have also been linked to several hematological 
malignancies, including T-cell acute lymphoblastic leukemia (T-ALL), acute myeloid 
leukemia (AML), lymphoma and multiple myeloma (MM) [6, 12]. The role of Notch 
signaling in hematopoiesis and in hematopoietic SC (HSC) development and maintenance 
has been extensively reviewed by Bigas and Espinosa [30], the fundamental finding being 
that activation of the Notch pathway is necessary for HSCs maintenance, and its inhibition 
results in HSCs differentiation and depletion [31].  The role of Notch signaling in the 
biology of leukemic SCs (LSCs), however, appears to be context-dependent and requires 
further study before its importance is completely understood in these diseases [31]. 
 
Cancer Testis Antigens 
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Cancer Testis Antigens (CTA) are a sub-class of tumor associated antigens first cloned by 
van der Bruggen et al. in 1991 [32].  CTA expression is mainly restricted to the testis and 
neoplastic cells of various histological origins, with the vast majority of these molecules 
having negligible or no expression in normal somatic cells [33-43]. This restricted 
expression pattern depends on methylation of upstream control elements and can be 
altered by DNA methyl-transferase-1 inhibitors, such as 5-aza-2-deoxycytidine, and  
histone deacetylase (HDAC) inhibitors [44]. Since cancer is characterized by global 
genomic hypomethylation, CpG island hypomethylation is likely to represent a major 
mechanism for re-activation of CTA transcriptional expression in cancer.  Simpson et al. 
have recently suggested that CTA expression in cancer cells may be the result of re-
activation of a gametogenic program as part of the process of neoplastic transformation 
[45].  Indeed, a number of CTAs normally expressed at various stages of gametogenesis 
have also been found in cancer cells, suggesting the triggering event is re-activation of a 
germ cell developmental program [45].  This theory supports the recent observation that 
some CTAs are expressed in TICs, cells characterized by self-renewal abilities similar to 
germ cells.    
The possibility that CTAs may be expressed by TICs suggests these molecules may 
also serve as therapeutic targets.  TIC-specific interventions, such as vaccines and/or 
other immunotherapeutic approaches targeting CTAs, may result in eradication of this self-
renewal cell population and increased cure rates in specific malignancies.  In fact, their 
restricted tissue expression, high immunogenicity and presence of HLA-I-restricted 
epitopes, make CTAs ideal candidates for the immunotherapeutic targeting of cancer [36, 
46, 47].  So far, most CTA-specific vaccines have targeted CTAs such as MAGE-A, NY-
ESO-1, and SSX, with variable success [48, 49]. More recently, a novel group of CTAs 
belonging to the sub-group of scaffolding sperm proteins, namely SP17, AKAP-4 and 
Ropporin-1, have shown promise as targets for immunotherapeutic interventions in certain 
malignancies [33, 36, 40, 41, 50-52].  Among these, only SP17 has been evaluated in the 
clinical setting [53].  In this study, SP17-loaded autologous dendritic cells (DCs) were used 
to treat a MM patient, who had developed disease progression, and resulted in SP17-
specific immunity and reduction of serum paraprotein levels [53].  Based on these 
preliminary results, evaluation of this CTA sub-group of scaffolding sperm proteins is 
clearly warranted in a larger group of MM patients.  More importantly, further studies to 
unravel the link between CTA expression and TIC biology are necessary in order to 
develop effective TIC-targeted therapies in the future.    
Page 7 of 19
URL: http:/mc.manuscriptcentral.com/giri  Email: abot@mannkindcorp.com
International Reviews of Immunology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
 
CTAs as markers of tumor stemness  
The expression of CTAs by TICs, and the functional relation between CTAs and cell 
stemness, has become an active area of research.  It has been suggested that CTA 
expression may play a role in SC differentiation pathways and embryonic development.   
For example, during embryonic development the epiblast gives rise to mesenchymal SCs 
(MSCs) and primordial germ cells with active CTA expression programs [54].  
Differentiation of these primordial cells results in down-regulation of CTA expression and 
may explain why CTAs are not detected in spermatocytes or oocytes, but are present in 
gametagonia [54].  In addition to other processes associated with SCs, such as the level of 
histone acetylation and lack of cellular differentiation, CTAs may serve as markers of 
stemness in specific neoplasms.  The role of CTAs as SC markers is supported by the 
detection of CTA expression in bone marrow MSCs. Expression of CTAs, such as NY-
ESO-1, MAGE1, SSX and N-RAGE, has been shown to be down-regulated in adipocytes 
and osteocytes after their complete differentiation from MSCs [55].  CTA expression may 
also confer a functional advantage to cancer cells by modulating their invasive and 
metastatic potential.  For example, SSX down-regulation in melanoma cells results in 
decreased expression of matrix metalloprotease-2 (MMP2) and migration potential [56].  
Since the process of malignant transformation may be defined by mutational deregulation 
of SC programs for self-renewal and differentiation, CTA expression may serve, not only 
as a potential marker of tumor cell stemness, but as an attractive target for treatment of 
TIC-dependent metastatic, recurrent and/or resistant disease [57].  
 Expression of CTAs in tumor SCs or TICs has been evaluated in several tumor 
models.  GBM is a primary glial malignancy believed to have a defined SC population [58].  
CD133 expression has been suggested as a marker of stemness in this malignancy based 
on the observation that CD133 positive cells can give rise to tumorigenic cells [58,59].  
Interestingly, CTAs such as LAGE-1, NY-ESO-1 and MAGE family members are also 
expressed in GBM CD133 positive cells, compared with differentiated or parent cells [59]. 
Moreover, the expression of MAGE family members and CD133 is down-regulated as cells 
become more differentiated, indicating a correlation between expression of these 
molecules and the undifferentiated cellular state [59].  Since CD133 negative GBM cells 
can also be tumorigenic [58], CD133 expression can’t be considered a specific marker for 
GBM stemness.  Therefore, determination of expression of certain CTA expression 
patterns could be helpful in determining cellular stemness among CD133 negative GBM 
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cell populations.  Studies with MM clonogenic precursors (CD138 negative B cells thought 
to be MM SCs) have also revealed expression of MAGE A3/A6 and MAGE-C1/C7, as well 
as the protective role these CTAs confer against apoptosis [60].  MSCs can also give rise 
to TICs with specific neoplastic characteristics and it has been suggested these TICs 
comprise the main cellular compartment expressing CTAs within a given tumor [56, 57].  
Gjerstorff et al. have found high levels of expression of several CTAs, such as CAGE, 
MAGE-A and XAGE-1, in tumorigenic MSCs, as opposed to primary human MSCs [57].  
These observations support the notion that CTA expression may be associated with 
neoplastic transformation of normal SCs.  Since promoter hypomethyation is one of the 
main regulatory mechanisms involved in CTA expression, changes on CTA-specific 
epigenetic control mechanisms may help differentiate neoplastic (i.e., TIC) from normal 
SCs.   This distinction is important since it could have both therapeutic and prognostic 
implications.  
 
Interactions between Notch signaling and CTA expression in TICs: Lessons from 
MM.  
The discovery of embryonic, germinal and tumor-restricted expression of CTAs has 
advanced the hypothesis of a functional correlation between embryogenesis, 
gametogenesis, and tumorigenesis [61,62]. These observations have partially resurrected 
John Beard's "Trophoblastic Theory of Cancer" proposing that all tumors carry a 
population of cells with germ-like features originating from germinal cells which have failed 
to migrate to the gonads [63].  Thus, aberrant CTA expression in tumors may reflect re-
activation of a gametogenic program involved in maintenance of stemness in specific 
cellular compartments, such as TICs [62].  As previously discussed, there is evidence 
supporting the hypothesis that the Notch pathway may also be associated with reactivation 
of a germinal cell transcription program in TICs.  Since Notch signaling is an important 
regulator of germ cell development, it is likely that the common expression pattern shared 
by Notch1 and CTAs in germ cells [14-18] reflects a biologically relevant interaction 
between these two pathways.   
Several CTAs are expressed in MM cells and their expression appears to play an 
important role in cell proliferation and resistance to apoptosis [60, 64-67].  Our group was 
the first to identify expression of two novel CTAs, AKAP-4 and SP17, in more than 75% of 
MM cell lines and patients [37].  Jungbluth et al. have reported expression of MAGE-C1 
and MAGE-A3/6 in MM, their expression correlating with MM cell proliferation [68].  CTA 
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expression in MM appears to occur early in the evolution of this disease and maintained 
thorough clinical progression, suggesting CTA expression may confer a selective 
advantage to MM neoplastic cells [69]. CTA expression in malignant MM cells has also 
been correlated with the activation of Notch signaling through the Jagged-2 ligand [70].  
Moreover, activation of Notch signaling has been associated with drug resistance, as well 
as cross-talk between MM cells and bone marrow microenvironment [71,72], the latter 
being a critical requirement for  maintenance of MM SC population [67].   
In vitro and in vivo studies support a “compartmental model” for MM.  In this model 
two cellular compartments exist: 1. a small, proliferating fraction of self-renewing 
progenitor cells (the so called MM SC); 2.  a non-proliferating compartment exhibiting 
plasma cell differentiation and resistance to apoptosis [73].  Here, we propose a different 
model in which Notch signaling and CTA expression interact to maintain a self-replicating  
MM cell population.  Although CTA expression has been described in a broad range of 
solid and hematologic malignancies [33,35,36,39,40,41,43], MM is distinct in that a 
significant majority of patients express AKAP-4 and/or SP17 in their tumor cells [34,37,38, 
42]. No other type of cancer has such a close association with specific CTA expression 
pattern. To date, the molecular and biological actions of SP17 and AKAP4 are 
incompletely understood. Nonetheless, several reports have implicated SP17 in cell-to-cell 
adhesion and/or cell migration of lympho-hematopoeitic cells, possibly through its heparan 
sulphate binding domain [74].  SP17 has two additional functional domains, an N-terminal 
domain highly conserved among mammals and 45% identical to the type II alpha 
regulatory subunit of protein kinase A (RII-PKA) and a C-terminal calmodulin binding 
domain [75,76].  AKAPs represent a family of proteins characterized by their ability to bind 
and regulate PKA function by localizing this critical enzyme to specific sub-cellular 
compartments.  Its structural homology to a PKA regulatory subunit suggests a potential 
role for SP17 in signal transduction. In fact, non-PKA proteins containing an RII-PKA-like 
domain at their N-terminal, such as Sp17, can interact with AKAPs via hydrophobic 
residues [75]. For example, Lea et al. have demonstrated  SP17 can bind the RII-PKA 
binding site of AKAP3, the most abundant AKAPs in the fibrous sheath of mouse flagella 
of spermatozoa [77].  This finding suggests a mechanism by which SP17 may regulate 
PKA-dependent processes.  By physically interacting with AKAPs RII-PKA binding site, 
SP17 may disrupt the primary interaction of between AKAPs and PKA, resulting in mis-
localization of PKA and interference with its activity at specific subcellular compartments, 
as well as modulation of other critical signal transduction pathways related to PKA 
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activation.  Alternatively, and by virtue of AKAP-specific anchoring to subcellular locations, 
AKAP-bound SP17 may be translocated to specific compartments where it may exert, as 
of yet, unknown biological functions.   
Activation of AKAP proteins can also occur under a variety of stimuli leading to 
increase intracellular cAMP levels and consequent PKA activation [78].  Interestingly, a 
role for PKA signaling in Notch activation has been clearly demonstrated by Weber and 
colleagues [79]. The investigators showed that treatment of osteoclasts with parathyroid 
hormone (PTH) induces a cAMP/PKA-dependent 8-fold increase in Jagged1 expression. 
This finding is particularly relevant since Jagged1-mediated Notch activation has been 
shown to drive proliferation of MM cells [70]. Another clue pointing to a role of PKA 
signaling in Notch activation has been provided by a study by Yurugi-Kobayashi and 
colleagues showing that cAMP-dependent PKA activation leads to suppression of COUP-
TFII expression, up-regulation of NRP1, and consequent Notch activation, in vascular 
progenitor cells [80]. These findings indicate a possible role for SP17 and/or AKAP-4-
dependent PKA activation in the regulation of Notch ligand expression (Figure 1). 
Therefore, coordination of SP17/AKAP4 expression and Notch signaling may result in 
enhanced self-renewal and survival abilities of MM TIC compartment.  Taken together, 
these data suggest SP17 may play a regulatory role in the activation of important signal 
transduction pathways by modulating the interaction between PKA and AKAPs. SP17 
could also participate, through its RII-like N-terminal domain and the central heparan 
sulphate binding domain, in key developmental processes such as cell migration and 
Hedgehog signal transduction [81-83].   
 
Future perspectives: immunotherapeutic implications 
Cancer vaccines represent the most advanced immunotherapeutic approach for 
oncologic patients.  Classically, cancer vaccines are designed to exploit tumor targets 
derived from cancer-inducing infectious agents and/or tumor-associated antigens. We 
believe CTAs represent ideal cancer antigenic targets based on their selective expression 
in immune privileged sites (i.e., testes) and neoplasms, but not in normal cells.  Moreover, 
the expression of CTAs by TICs, represent a powerful target for immunotherapeutic 
interventions that may eradicate this fundamental and aberrant cellular compartment 
responsible for initiation and maintenance of the neoplastic clone.  With the discovery of 
TIC-associated CTA expression the possibility of improving disease-free survival and cure 
rates in cancer patients may become a reality.  The efficacy of TIC-targeting vaccines has 
Page 11 of 19
URL: http:/mc.manuscriptcentral.com/giri  Email: abot@mannkindcorp.com
International Reviews of Immunology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
been explore with some success in acute myeloid leukemia (AML) [84].  However, the lack 
of AML-TIC-restricted targets raises concerns about potential toxicities, which in principle 
could be minimized by targeting TIC-associated CTAs [85].   
It is evident that any strategy designed to increase expression of cancer-restricted 
antigens would result in better responses to cancer vaccine strategies [86].  Regulation of 
CTA expression in tumors of different histological origin is based on epigenetic tuning of 
promoter availability and chromatin remodeling [87-90].  Notch signaling has been shown 
to down-regulate the expression of specific targets by increasing promoter methylation in 
genes such as pRb and vascular endothelial growth factor receptor (VEGFR)-2 [91]. 
Therefore, the possibility exists that Notch signaling may contribute to mitigate the 
expression of CTAs in selected tumoral sub-populations, such as TICs.  In this scenario, 
Notch-inhibiting agents, in combination with CTA-targeting vaccines, would improve  
therapeutic efficacy by increasing the probability of TIC eradication.  Additionally, inhibition 
of Notch signaling by itself is expected to reduce the self-renewal ability of TICs, which 
would then make these cells more susceptible to CTA-specific cytotoxic lymphocyte killing.  
The potential drawback of this approach, however, would be the lack of tumor specificity of 
Notch targeting, compared with CTA targeting.  Currently, the only strategy tested in 
patients to inhibit Notch signaling is the use γ-secretase inhibitors, which results in serious 
gastrointestinal toxicity due to induction of intestinal metaplasia, a consequence of 
deregulation of goblet cell differentiation in the int stine [92,93].  Intestinal metaplasia is 
caused by the concurrent inhibition of both Notch1 and 2, indicating independent targeting 
of Notch1 or Notch2 specific antibodies may eliminate the observed toxicity, as 
demonstrated animal models of acute leukemias [94].  The use of antibodies that 
specifically block tumor-associated Notch isoforms, and/or their ligands, represent a 
potential alternative to toxic demethylating agents, such as 5-aza-2'-deoxycytidine, and γ-
secretase inhibitors [95].  As discussed above, selective Notch blockade would result in 
increased CTA expression by TICs making these more susceptible to the cytotoxic effects 
of therapeutic cancer vaccines.  To date, several clinical trials are evaluating the safety 
and efficacy of Notch inhibition in both solid and hematological malignancies, including MM 
(www.clinicaltrials.gov).  These studies should provide the necessary information to design 
future clinical trials combining Notch inhibition and CTA overexpression and immuno-
targeting for the treatment of selective cancers [86,95,96].    
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Figure legends 
Figure 1. Possible role of CTA signaling in Notch activation in MM. CTA (i.e. SP17, AKAP4) 
could directly enhance Notch activation by stabilizing the Notch intracellular domain (1), or they 
could activate PKA through cAMP increase, which may lead to Notch ligand Jagged1-
2overexpression, eventually resulting in Notch activation and consequent MM TIC self-renewal. 
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